Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations.
Zheng X, Chen Z, Guo M, Liang H, Song X, Liu Y, Liao Z, Zhang Y, Guo J, Zhou Y, Zhang ZM, Tu Z, Zhang Y, Chen Y, Zhang Z, Lu X.
Zheng X, et al. Among authors: zhang z, zhang zm, zhang y.
ACS Pharmacol Transl Sci. 2024 Apr 11;7(5):1485-1506. doi: 10.1021/acsptsci.4c00071. eCollection 2024 May 10.
ACS Pharmacol Transl Sci. 2024.
PMID: 38751627